<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828230</url>
  </required_header>
  <id_info>
    <org_study_id>BUF-17/RAP</org_study_id>
    <secondary_id>EudraCT No.: 2007-002082-13</secondary_id>
    <nct_id>NCT00828230</nct_id>
  </id_info>
  <brief_title>Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled, Multicentre, Comparative Phase II Pilot Study on the Efficacy and Tolerability of an 8-week Rectal Treatment With 2 mg Budesonide or Placebo for the Prevention of Acute Radiation Proctitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To proof the superiority of an 8-week rectal treatment with once-daily 2 mg budesonide versus&#xD;
      placebo for the prevention of acute radiation proctitis, and to evaluate the occurrence of&#xD;
      chronic radiation proctitis 1 year after start of radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was prematurely stopped due to slow recruitment after 17 of 32 anticipated patients were&#xD;
    recruited.&#xD;
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients developing radiation proctitis during treatment or need rescue medication</measure>
    <time_frame>within 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to occurrence of acute radiation proctitis</measure>
    <time_frame>During 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to occurrence of chronic radiation proctitis</measure>
    <time_frame>Within 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>During 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Radiation Proctitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg rectal budesonide per day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One application of placebo foam once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide</intervention_name>
    <description>One application of 2mg budesonide once daily for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Budenofalk rectal foam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo foam</intervention_name>
    <description>One application of placebo foam once daily for 8 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent,&#xD;
&#xD;
          -  Men aged at least 18 years,&#xD;
&#xD;
          -  Patients with ECOG performance status &lt;= 2 or Karnofsky Performance Status Scale &gt;=&#xD;
             70%,&#xD;
&#xD;
          -  Estimated life expectancy more than 3 years,&#xD;
&#xD;
          -  Diagnosis of prostate carcinoma,&#xD;
&#xD;
          -  Indication for local RT in patients with prostatic cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Crohn's disease, indeterminate colitis, ulcerative colitis, microscopic colitis (i.e.,&#xD;
             collagenous colitis and lymphocytic colitis),&#xD;
&#xD;
          -  Severe or symptomatic ischaemic colitis at baseline,&#xD;
&#xD;
          -  Grade III internal haemorrhoids at baseline,&#xD;
&#xD;
          -  High risk patients needing extended radiation therapy,&#xD;
&#xD;
          -  Acute EORTC/RTOG lower GI toxicity score of &gt;=1 at baseline,&#xD;
&#xD;
          -  Bacterial, amoebic, fungal, or viral infections of the gut,&#xD;
&#xD;
          -  Tuberculosis, hypertension, infection, diabetes mellitus (included familiarly&#xD;
             predisposition), active peptic ulcer, osteoporosis, glaucoma, or cataract, if careful&#xD;
             medical monitoring is not ensured,&#xD;
&#xD;
          -  Portal hypertension or liver cirrhosis,&#xD;
&#xD;
          -  Abnormal hepatic function (ALT, AST or AP &gt; 2.5 x ULN),&#xD;
&#xD;
          -  Known intolerance/hypersensitivity/resistance to study drug or drugs of similar&#xD;
             chemical structure or pharmacological profile, or to any of the other constituents of&#xD;
             the study drug,&#xD;
&#xD;
          -  Participation in another clinical trial within the last 30 days, simultaneous&#xD;
             participation in another clinical trial, or previous participation in this trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Mueller, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Falk Pharma GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Radioonkologie und Strahlentherapie - Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strahlentherapie, St. Vincentius-Kliniken gAG</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strahlentherapie, Klinikum Mutterhaus der Borromäerinnen</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2009</study_first_posted>
  <last_update_submitted>January 26, 2012</last_update_submitted>
  <last_update_submitted_qc>January 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>budesonide</keyword>
  <keyword>placebo</keyword>
  <keyword>acute radiation proctitis</keyword>
  <keyword>late radiation proctitis</keyword>
  <keyword>Prevention of acute radiation proctitis</keyword>
  <keyword>Prevention of late radiation proctitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proctitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

